Real-life quitters star in NiQuitin Stoptober push
This article was originally published in OTC Bulletin & The Rose Sheet
Smokers who have successfully kicked the habit using NiQuitin are at the heart of Perrigo’s new £1.2 million (€1.3 million) campaign for the nicotine-replacement therapy brand in the UK.
You may also be interested in...
Perrigo's 'New Year, New You' UK campaign for its smoking cessation brand NiQuitin returns in 2019 with a new 'real life quitter' television spot.
Public Company Edition: Cancer-focused Adlai Nortye launched a concurrent initial public offering and private placement, while four other drug developers announced or completed SPAC mergers. Also, Sobi grossed $540m in a rights issue and Immunovant followed early data with a $450m FOPO.
The company anticipates potential sales in excess of $1bn for the late-onset Pompe disease drug by the end of the decade.